Top Markets
Coin of the day
Elicio Therapeutics, Inc. Elicio Therapeutics, Inc.

Elicio Therapeutics, Inc.

ELTX
Pozycja w akcjach #24601
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to... Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.
Cena akcji
$3.09
Kapitalizacja rynkowa
$58.82M
Zmiana (1 dzień)
0.33%
Zmiana (1 rok)
-73.01%
Kraj
US
Handel Elicio Therapeutics, Inc. (ELTX)

Kategoria

Historia ceny akcji dla Elicio Therapeutics, Inc. (ELTX)
Najwyższa cena zamknięcia: $3.10 dnia 2026-08-01

Najniższa cena zamknięcia: $5.88 dnia 2023-11-01
Historia cen akcji firmy Elicio Therapeutics, Inc. od 2023 do 2026
Roczna wydajność ceny akcji
Rok Wydajność
2026 (TTM) 9.17%
2025 59.27%
2024 -21.55%
2023 0.00%
Cena akcji podobnych firm lub konkurencji
Firma Cena akcji Zmiana 1r% Kraj
$549.84 38.34%
US
$1.05K 58.20%
NL
$150.50 473.99%
US
$118.70 -18.24%
AU
$770.19 9.84%
CH